Utah Retirement Systems maintained its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,400 shares of the biopharmaceutical company’s stock at the end of the first quarter. Utah Retirement Systems’ holdings in ACADIA Pharmaceuticals were worth $599,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently modified their holdings of ACAD. Russell Investments Group Ltd. purchased a new position in shares of ACADIA Pharmaceuticals during the fourth quarter worth approximately $145,000. State Board of Administration of Florida Retirement System boosted its position in shares of ACADIA Pharmaceuticals by 8.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 111,511 shares of the biopharmaceutical company’s stock worth $3,216,000 after buying an additional 9,134 shares in the last quarter. State Street Corp boosted its position in shares of ACADIA Pharmaceuticals by 7.9% in the fourth quarter. State Street Corp now owns 3,354,026 shares of the biopharmaceutical company’s stock worth $96,728,000 after buying an additional 246,198 shares in the last quarter. A.R.T. Advisors LLC purchased a new position in shares of ACADIA Pharmaceuticals during the fourth quarter worth approximately $348,000. Finally, Guggenheim Capital LLC boosted its position in shares of ACADIA Pharmaceuticals by 4.2% in the fourth quarter. Guggenheim Capital LLC now owns 135,350 shares of the biopharmaceutical company’s stock worth $3,903,000 after buying an additional 5,472 shares in the last quarter. 97.19% of the stock is currently owned by hedge funds and other institutional investors.
ACADIA Pharmaceuticals Inc. (ACAD) opened at 29.01 on Tuesday. The firm has a 50-day moving average price of $28.10 and a 200-day moving average price of $32.03. ACADIA Pharmaceuticals Inc. has a 52 week low of $20.68 and a 52 week high of $40.83. The company’s market capitalization is $3.54 billion.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.72) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.01. ACADIA Pharmaceuticals had a negative return on equity of 63.07% and a negative net margin of 948.93%. The business had revenue of $15.30 million for the quarter, compared to the consensus estimate of $15.17 million. During the same period in the previous year, the business earned ($0.45) earnings per share. Analysts anticipate that ACADIA Pharmaceuticals Inc. will post ($2.83) EPS for the current fiscal year.
WARNING: “Utah Retirement Systems Holds Position in ACADIA Pharmaceuticals Inc. (ACAD)” was published by sleekmoney and is the sole property of of sleekmoney. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://sleekmoney.com/utah-retirement-systems-holds-position-in-acadia-pharmaceuticals-inc-acad/1942799.html.
A number of research analysts have recently commented on ACAD shares. Vetr cut ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating and set a $41.20 price target on the stock. in a research report on Monday, February 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $49.00 price target on shares of ACADIA Pharmaceuticals in a research report on Wednesday, March 1st. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of ACADIA Pharmaceuticals in a research report on Friday, March 3rd. Zacks Investment Research raised ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 7th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $47.00 price target on shares of ACADIA Pharmaceuticals in a research report on Wednesday, April 12th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and ten have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $42.88.
In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 1,903 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $30.00, for a total transaction of $57,090.00. Following the sale, the executive vice president now directly owns 83,059 shares of the company’s stock, valued at $2,491,770. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 22.25% of the stock is currently owned by insiders.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/utah-retirement-systems-holds-position-in-acadia-pharmaceuticals-inc-acad/1942799.html
Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.